TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

After years of research, scientists in China have created a bone-free fish, which has been named 'Zhongke No. 6'. The new ...

In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...

Corynebacterium glutamicum S9114, a superior strain widely used in glutamic acid industrial production through traditional mutagenesis screening, is ...

Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...

Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting ...

Dlc1 deletion affects cardiac differentiation in mouse embryonic stem cells by activating the canonical Wnt pathway ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...